September 16, 2025Open Access

Human CART22.19 Therapy in Refractory Pediatric B-ALL: Insights from a Named-Patient Cohort

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Named-patient cohort demonstrates CART22.19 therapy's efficacy in refractory pediatric B-ALL cases, suggesting improved outcomes.

CART22.19 achieved an initial complete molecular remission in 78% of patients, indicating it may effectively treat resistant B-ALL.
Cytokine release syndrome occurred in 38.5% of infusions, but was managed without severe adverse events, emphasizing safety.
The method utilized autologous and donor-derived CAR22.19 T-cells manufactured via a GMP-compliant process for all patients.
Challenges remain, notably the limited persistence of CAR T-cells, which can hinder long-term remission in this high-risk population.

Mast et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

September 16, 2025Open Access

View Full Paper

Ask AI

Bookmark

Authors

Named-patient cohort demonstrates CART22.19 therapy's efficacy in refractory pediatric B-ALL cases, suggesting improved outcomes.

CART22.19 achieved an initial complete molecular remission in 78% of patients, indicating it may effectively treat resistant B-ALL.
Cytokine release syndrome occurred in 38.5% of infusions, but was managed without severe adverse events, emphasizing safety.
The method utilized autologous and donor-derived CAR22.19 T-cells manufactured via a GMP-compliant process for all patients.
Challenges remain, notably the limited persistence of CAR T-cells, which can hinder long-term remission in this high-risk population.

Mast et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark